Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
In the present study, a TF-based robust MYC-estrogen related receptor α-regulatory factor X5 (MYC-ESRRA-RFX5) signature was developed for predicting the survival of patients with renal cell carcinoma.
|
31423259 |
2019 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The expression levels of ACLY, ENO1, ZIK1, AKR1C3 and MYC in RCC were higher than those in normal kidney (p<0.05, all of above factors).
|
28739731 |
2017 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found an association between MYC levels and PVT1 expression, which impacted on MYC-target genes.Collectively, our study discloses the role of PVT1 as a novel prognostic factor and as a molecular target for novel therapeutic interventions in renal carcinoma.
|
27366943 |
2016 |
Renal Cell Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Our studies demonstrate that MYC overexpression causes RCC and points to the inhibition of glutamine metabolism as a potential therapeutic approach for the treatment of this disease.
|
25964345 |
2015 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Most RCC result from Von Hippel-Lindau (VHL) tumor suppressor loss-of-function and subsequent gain-of-function of the oncogenic HIF-2alpha/c-MYC pathway.
|
24657971 |
2014 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Moreover, based on the results of this analysis, we investigated whether miR-135a targeted the c-MYC gene in RCC.
|
23176581 |
2013 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results suggest for the first time that let-7a acts as a tumor suppressor in RCC cell lines by down-regulating c-myc and c-myc target genes such as proliferating cell nuclear antigen (PCNA), cyclin D1 (CCND1) and the miR17-92 cluster, which is accompanied by proliferation inhibition and cell cycle arrest.
|
22155254 |
2012 |
Renal Cell Carcinoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In RCC group, c-MYC expression was significantly higher in RCC tissues compared with normal tissues (P < 0.05).
|
21982273 |
2011 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
LHGDN |
MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells.
|
18809243 |
2009 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
LHGDN |
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.
|
19061835 |
2008 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
LHGDN |
The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dubé gene pathway.
|
18206534 |
2008 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
RGD |
Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway.
|
18055543 |
2007 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The importance of MYC activation was confirmed by both pharmacologic and short interfering RNA-mediated inhibition of active Myc signaling in a cell line model of type 2 papillary RCC.
|
17409424 |
2007 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
PFG analysis of DNA containing the t(3;8) rearrangement shows that the breakpoint is not located in the mapped region, making it unlikely that MYC is involved in this form of renal cell carcinoma.
|
2914707 |
1989 |
Renal Cell Carcinoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The possible role that the relocation of c-myc might have on the development of renal carcinoma in carriers of this 3;8 translocation was further studied by analysis of the region surrounding the c-myc gene.
|
3536362 |
1986 |
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
The translocated c-myc gene should provide a probe to the chromosome 3p14 region, which appears to be important not only in renal cell carcinoma but also in small cell carcinoma of the lung.
|
2995998 |
1985 |